Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | ECE1 | P42892 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 4/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | RPA1 | P27694 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995503 | 1.00 | ATM (0.43) | ATMCTSSCTSKMMEL1AAK1 | |
| SCHEMBL3992019 | 0.89 | ATM (0.45) | ATMCTSSCTSKMMEL1AAK1 | |
| SCHEMBL3992025 | 0.89 | ATM (0.45) | ATMCTSSCTSKMMEL1AAK1 | |
| SCHEMBL3995427 | 0.88 | MME (0.44) | ATMCTSSCTSKMMEL1AAK1 | |
| SCHEMBL3995348 | 0.84 | CTSS (0.50) | CTSSCTSKECE1BCL2CTSB | |
| SCHEMBL3991843 | 0.80 | ATM (0.38) | ATMCTSSCTSKECE1MME | |
| SCHEMBL6500000 | 0.79 | SERPINE1 (0.41) | CTSSCTSKECE1MMP2MMP3 | |
| SCHEMBL6499998 | 0.79 | SERPINE1 (0.41) | CTSSCTSKECE1MMP2MMP3 | |
| SCHEMBL4832114 | 0.79 | CTSS (0.47) | CTSSCTSKECE1BCL2CTSB | |
| SCHEMBL4832110 | 0.79 | CTSS (0.47) | CTSSCTSKECE1BCL2CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | ATM 4214/4885CTSS 1245/4885CTSK 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.